This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Ramipril

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Ramipril is an ACE-inhibitor. Two important clinical trials involving the use of ramipril were the AIRE study and the HOPE study.

Indications for ramipril include:

  • reducing the risk of myocardial infarction, stroke, cardiovascular death or need for revascularisation procedures in patients of 55 years or over who have clinical evidence of cardiovascular disease
  • reducing the risk of myocardial infarction, stroke, cardiovascular death or need for revascularisation procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings (hypertension, high total cholesterol (>5.2 mmol/l), low HDL (<0.9mmol/l), current smoker, known microalbuminuria, clinical evidence of previous vascular disease
  • mild to moderate hypertension
  • congestive heart failure - may be used as adjunctive therapy to diuretics with or without cardiac glycosides

The summary of product characteristics should be consulted before prescribing this drug.


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page